Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 19/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7680445 | 0.88 | NR1I2 (0.72) | CASRNR1I2EGFRADRA2AADORA3 | |
| SCHEMBL13347126 | 0.83 | CASR (0.76) | CASRNR1I2EGFRADRA2AADORA3 | |
| SCHEMBL13347113 | 0.82 | CASR (0.74) | CASR | |
| SCHEMBL13347117 | 0.82 | CASR (1.00) | CASR | |
| SCHEMBL13347536 | 0.80 | CASR (0.55) | CASRNR1I2EGFRADRA2AADORA3 | |
| SCHEMBL13347576 | 0.80 | CASR (0.76) | CASRNR1I2EGFRADRA2AADORA3 | |
| SCHEMBL13347520 | 0.80 | CASR (0.78) | CASR | |
| SCHEMBL13347121 | 0.80 | CASR (1.00) | CASR | |
| SCHEMBL13347136 | 0.79 | CASR (1.00) | CASR | |
| SCHEMBL13347526 | 0.78 | CASR (0.73) | CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476286-B2 | for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476286-B2 | for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| EP-2191832-A1 | QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | Novartis AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| EP-1401451-B1 | QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |